#United States #Ibezapolstat #Staten Island #Acurx Pharmaceuticals #Antibiotics

Acurx Pharmaceuticals Reports Third Quarter Results

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP), a biopharmaceutical company focused on developing innovative antibiotics for challenging bacterial infections, recently shared their financial and operational outcomes for the third quarter of 2025, concluding on September 30. With an emphasis on antibiotic advancements, the company provided critical updates influencing their market position.

Significant Developments

Among the noteworthy accomplishments in the third quarter was the execution of a 1-for-20 reverse stock split on August 4, 2025, a move that strengthened their compliance with Nasdaq's minimum bid price rule. As of August 26, Acurx regained compliance, and now with a stockholder equity exceeding $2.5 million, they are fully aligned with all Nasdaq listing requirements. This represents a positive turnaround, ensuring their stock remains traded on the Nasdaq platform.

In September, Acurx celebrated the issuance of a new patent from the Australian Patent Office covering its class of DNA polymerase IIIC inhibitors, crucial for treating infections caused by Gram-positive bacteria, including those notorious for antibiotic resistance like MRSA and VRE. With this development, Acurx has achieved significant patent protections globally, including four patents awarded in the U.S., Israel, Japan, and India, with similar applications underway in other regions.

Additionally, their special meeting of stockholders saw the approval for increasing the overall number of authorized shares of common stock from 200 million to 250 million, supporting future capital needs and organizational flexibility. This amendment was filed with Delaware's Secretary of State in September.

In terms of immediate financial improvements, Acurx reported a raise of approximately $1.4 million from the exercising of Series F Warrants in October, which contributed to strengthening their cash position to around $5.9 million at the close of the quarter, compared to $3.7 million at the end of the previous year.

R&D and Operational Expenses

Moving into research and development costs, the company reported a drop in expenses for the third quarter, posting $0.4 million versus $1.2 million from the same time period last year. This decrease can be attributed to reduced consulting costs along with manufacturing expenditure declines.

In contrast, general and administrative costs held steady at $1.6 million over both periods, reflecting a balancing act where slight decreases in compensation expenses were negated by rising legal fees. For nine months ending in September, total operational expenses declined, underscoring effective cost management strategies undertaken by the company.

Clinical Advancements

In a significant presentation at the IDWeek conference in Atlanta in October, Acurx showcased updates on ibezapolstat, their lead antibiotic candidate aimed specifically at treating Clostridioides difficile infection (CDI). Throughout the presentation, the potential microbiome-sparing features of ibezapolstat were a focal point alongside new data from advanced mouse infection studies, demonstrating a defined microbiome-sparing effect. Key presenters included Dr. Michael Silverman and Dr. Kevin Garey from the University of Houston.

A turning point for Acurx occurred in November when they announced the publication of research in the renowned Nature Communications journal, resulting from collaboration with Leiden University Medical Center. The findings detailed the first structural biology analysis of ibezapolstat binding to its target, a significant milestone in the ongoing development of this novel antibiotic class.

Financial Overview

Acurx showed a net loss of $2.0 million for Q3 2025, demonstrating an improvement compared to a net loss of $2.8 million in Q3 2024. On a year-to-date basis, the losses also decreased from $11.3 million in 2024 to $6.4 million, showcasing operational efficiencies that yield better financial outcomes. Up to September 30, 2025, the company had around 1.8 million shares outstanding, demonstrating confidence in their strategic direction.

Future Outlook

As Acurx Pharmaceuticals navigates through its developmental journey, the upcoming Phase 3 trials for ibezapolstat remain on track, given the regulatory guidance received from the EMA and the FDA. The company's ambition to pioneer novel antibiotics is crucial in our fight against resistant bacterial infections, making their advancements not only a corporate highlight but a significant contribution to public health. Their upcoming conference call on November 12, 2025, led by CEO David P. Luci and CFO Robert G. Shawah, is anticipated to further elaborate on these points and reflect on the company's strategic future.

To gain more insights into Acurx Pharmaceuticals and its innovative pipeline of antibiotics, you can visit their official site at www.acurxpharma.com.